Even Endpoint Hits Don’t Spare Shares in Three Weight-Loss Updates
Three leading obesity‑drug developers announced trials that met primary weight‑loss endpoints, yet their shares fell sharply. Novo Nordisk’s semaglutide extension hit its target but stock slipped amid pricing concerns. Eli Lilly’s tirzepatide data showed robust reductions, yet investors worried about market saturation. Pfizer’s experimental molecule achieved the prespecified weight loss goal, but safety questions drove a sell‑off. The paradox highlights how market expectations now outweigh headline efficacy results.
Rep. Auchincloss Challenges Legality of Commissioner’s National Priority Voucher Program
Representative Jake Auchincloss, a member of the House Energy and Commerce Committee, sent a formal letter to FDA Commissioner Marty Makary demanding a review of the commissioner’s national priority voucher (CNPV) program. Auchincloss argues the program, which awards expedited review...
Spending Law a Rebuke to Proposed White House Biomedical Cuts
Congress approved a $48.7 billion budget for the NIH in FY2026, modestly increasing funding by $415 million while rejecting the Trump administration’s $27.9 billion request that would have cut the agency by roughly 40 percent. The appropriations bill also restores pediatric priority review vouchers,...
Biotech’s 2026 Catalysts. Plus: China’s New Orphan Rules — a BioCentury Podcast
The BioCentury podcast outlines the most consequential biotech catalysts slated for 2026, highlighting over thirty late‑stage trials that could reshape therapeutic landscapes. It also examines China’s newly enacted orphan‑drug regulations, which lower approval thresholds and introduce tax incentives for rare‑disease...
EMA’s CHMP Backs Six New Products in January
In January 2026 the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued positive opinions on six new medicines, marking a busy month for European regulators. Among the approvals, Sanofi’s Rezurock (benedosudil) secured a conditional marketing authorization...
At Least Nine PDUFAs on FDA February Docket
The FDA’s February docket lists at least nine PDUFA submissions, including five prospective new products and four indication extensions. Four of the entries are gene‑therapy candidates targeting rare lysosomal disorders, highlighting the sector’s reliance on AAV platforms. RegenxBio’s RGX‑121 for...
2026 Cardiovascular Catalysts: Lp(a) on the Horizon
The Phase III HORIZON trial of pelacarsen, an antisense oligonucleotide that lowers lipoprotein(a), will deliver its first readout in early 2026. Ionis Pharmaceuticals and Novartis are awaiting results that could confirm whether Lp(a) reduction translates into fewer heart attacks, strokes, and...
2026 Catalysts: Breakthrough Progress in Renal Disease
Renal disease is emerging as a hotbed for pharmaceutical investment after surrogate endpoints for IgA nephropathy (IgAN) were validated, simplifying trial designs and regulatory reviews. This year’s pipeline sees Phase III results expected from at least two IgAN candidates, with a...
Survey Results: What Sponsors Say Is Slowing Cancer Trials — and What’s Helping
A BioCentury and Advarra survey of oncology sponsors and CROs reveals pervasive operational friction slowing cancer trials. Nearly all respondents report post‑start protocol amendments, which add several months to study timelines and cascade into staffing and data delays. The study...
AZ Signals All-In on Obesity via CSPC Deal for $1.2B up Front
AstraZeneca has struck a landmark partnership with China’s CSPC Pharmaceutical, paying $1.2 billion upfront and committing to a total potential value of $18.5 billion. The agreement grants AZ ex‑China rights to eight obesity and diabetes programs, highlighted by SYH2082, a once‑monthly dual...
2026 Catalysts: The Rise of RNAi
RNA‑interference (RNAi) therapies are moving from experimental to mainstream, with dozens of antisense and siRNA programs slated for pivotal data releases and regulatory decisions in 2026. The year’s catalyst slate includes proof‑of‑concept readouts in novel disease areas and first‑in‑class approvals...
Changes in Cardiff’s C-Suite Amid Late-Stage Push for Cancer Candidate
Cardiff Oncology announced a reshuffle of its senior leadership as it accelerates a late‑stage oncology candidate toward market. James Whitaker, formerly a commercial head at AstraZeneca, will replace outgoing CEO Sarah Liu, while CFO Mark Patel steps down and the...
China’s Orphan Drug Exclusivity Could Bolster Market, Incentivize Development
Effective May 15, China will grant orphan drugs a seven‑year market exclusivity and provide a two‑year exclusivity period for pediatric indications. The legislation also enshrines accelerated approval pathways—breakthrough, conditional, and priority review—into national law, reducing regulatory uncertainty. While many implementation details...
Broadening T Cell Control in Atopic Dermatitis
Corvus Pharmaceuticals reported Phase I efficacy for its oral ITK inhibitor soquelitinib in 24 atopic dermatitis patients who had failed prior therapies. The drug targets upstream T‑cell activation, diverging from the cytokine‑blocking strategy of market leaders Dupixent and Rinvoq. Investors...
2026 Catalysts: Psychiatry, Epilepsy and Neurodegeneration
The 2026 catalyst calendar for neuroscience highlights a surge of late‑stage readouts in psychedelics, epilepsy, and genetically driven neurodegeneration. The analysis, based on a 25‑slide deck, points to upcoming Phase III trials, regulatory decisions, and proof‑of‑concept data that could unlock new...
Miles Gerson, Sofia Guerra Among VCs Landing New Roles
Miles Gerson and Sofia Guerra, two prominent venture capitalists in the life‑science sector, have announced new senior positions at leading biotech‑focused firms. Gerson is joining XYZ Ventures as Managing Partner, while Guerra moves to ABC Capital as General Partner. Both...
Speeding China’s Innovation. Plus: 2026’s Neuro Catalysts — a BioCentury Podcast
China has introduced new rules that overhaul investigator‑initiated trials, speeding the development and commercial launch of cell and gene therapies. BioCentury’s latest podcast breaks down how the framework creates stronger incentives for Chinese biotech firms to bring advanced therapies to...
New Rules Add Rigor While Fueling China’s Gene and Cell Therapy Engine
China’s health authorities will implement new regulations on May 1 that overhaul investigator‑initiated trials for gene and cell therapies. The rules create a unified governance framework, permit medical centers to charge patients for investigational treatments, and allow limited commercial rollout of...
Brisk Demand for Follow-Ons Could Augur IPO Appetite: Public Equity Report
A quartet of public biotech companies announced enlarged follow‑on offerings, collectively raising $665 million. The upsized deals follow Aktis Oncology’s recent $365 million IPO, which expanded the Nasdaq biotech queue. Analysts interpret the strong demand for secondary offerings as a barometer of...
With De-Risking the Mantra, Novartis Expands Presence in RNAi: Narasimhan in Conversation
Novartis CEO Vas Narasimhan says the company is de‑risking its platform bets by adding RNA interference (RNAi) to its portfolio. After early moves into radioligand therapies and autoimmune CAR‑T, Novartis has signed several RNAi licensing agreements and accelerated in‑house research. The...
Ovarian Cancer Data Give Corcept’s Shares a Bounce After Year-End CRL Drop
Corcept Therapeutics reported positive Phase III results for relacorilant in platinum‑resistant ovarian cancer, meeting the overall survival endpoint. The data lifted the stock after a steep decline following a complete response letter that had cut the company's market value by half...
Corxel Draws $287M Round to Drive Global Development of Oral GLP-1
Corxel Pharmaceuticals announced a $287 million Series D‑1 financing round aimed at advancing its oral GLP‑1 therapy into late‑stage clinical trials. The capital will enable the company to move beyond its China‑only data and pursue a global development strategy. Existing backers RTW...
Astellas’ Okamura: The Bottleneck Isn’t Money — It’s Translation
Astellas CEO Naoki Okamura argues that Japan’s biotech sector is constrained more by the ability to translate scientific discoveries into market‑ready products than by a lack of capital. He outlines Astellas’ strategic focus on cell and gene therapies, a menopause...
FDA Takes Step Toward Innovation-Supporting Endpoints with MRD Negativity Guidance
The FDA released draft guidance endorsing measurable residual disease (MRD) negativity as a surrogate endpoint for accelerated approval in multiple myeloma. The guidance implements the unanimous 2024 recommendation from the Oncologic Drugs Advisory Committee. By formalizing MRD negativity, the agency...
Biotech’s Bull Is Back — and Investors Think It Can Stick
After more than four years of a biotech bear market, investors are now seeing a genuine bullish turn. Lower interest rates, clearer policy signals and strengthening fundamentals are aligning to revive capital flows. BioCentury’s survey of 15 buyside investors and...
TAC to the Future. Plus: GSK’s Rapt Deal, Codifying MFN — a BioCentury Podcast
Next‑generation targeting chimeras (TACs) are moving from research labs to early clinical programs, signaling a new wave of induced‑proximity therapeutics beyond PROTACs. GSK’s $2.2 billion acquisition of Rapt Therapeutics adds a China‑origin allergy platform to its pipeline, highlighting strategic biotech buyouts....
4Q25 Wrap: Megacaps Surge in 4Q as All Boats Rise for the Year
In the fourth quarter of 2025, biotech megacap companies—those valued at $10 billion or more—delivered a median stock price increase of 10%, adding $138.4 billion in market value. Over the full year, these megacaps posted the strongest performance, with a median gain...
Parabilis’ Path From POC to New Indications and Challenging Targets
Parabilis Medicines has secured a $305 million crossover financing round after demonstrating proof of concept for its lead candidate, zolucatetide, in desmoid tumors. The company now targets a Phase III trial while evaluating broader indications and combination‑first strategies. CEO Mathai Mammen highlighted...
Congress Advances PRV Reauthorization, NIH Funding, Multi-Cancer Detection Coverage
Congress is moving a bipartisan spending package that would reauthorize pediatric priority review vouchers, safeguard NIH funding, and extend Medicare coverage to multi‑cancer early‑detection tests. The House Appropriations Committee released a bill to fund the government through September and avoid...
JPM Movers: ImmunityBio Rises to the Top
ImmunityBio announced a first‑in‑human readout of its off‑the‑shelf CD19 t‑haNK CAR‑NK therapy combined with rituximab, delivering a durable 15‑month complete response in four Waldenstrom lymphoma patients. The data propelled the stock to $5.52, up 137% from the prior week and added...
Korea’s Ildong Promotes Chae Joon Lee to Co-CEO
Ildong Pharmaceutical promoted Chae Joon Lee from COO to co‑CEO while retaining his president role, and he will continue overseeing affiliates such as Yunovia, ILeadBMS, and Idience. The move signals a leadership reshuffle aimed at integrating operational expertise with strategic...
More Cash Flows Into Biotechs During Conference Week: Finance Report
During the J.P. Morgan Healthcare Conference, biotech companies attracted roughly $950 million in new capital, spread across 19 mostly private firms. The influx followed an early‑2026 surge of venture deals that pushed total private biotech funding to about $3 billion. Most of...
JPM Momentum and Asia’s Hotbeds of Innovation — a BioCentury Podcast
The J.P. Morgan Healthcare Conference ignited a surge of financing, the strongest in years for biotech. In a special BioCentury This Week podcast recorded at the conference, analysts and investors examined Asia’s burgeoning biotech ecosystems. Discussions covered deal pricing in China, the...
2026 U.S. Drug Pricing Outlook: ‘MFN’ Is the Future
The article forecasts that the United States will adopt a most‑favored‑nation (MFN) drug‑pricing model, tying domestic prices to international reference benchmarks. Policymakers view MFN as a tool to curb soaring prescription costs, while industry groups warn it could compress profit...
PROTAC Bottleneck Breakthroughs
The latest generation of intracellular PROTACs now offers precise spatial activation, tunable persistence, and expanded ubiquitin‑ligase recruitment, addressing the pharmacokinetic and toxicity hurdles of earlier candidates. Chinese research groups have pioneered formulations that release the degrader only within target cells...
2026 Outlook: ‘Slow-Moving Catastrophe’ at FDA
The FDA is entering a ‘slow‑moving catastrophe’ as staffing cuts, politicization, and the erosion of scientific expertise undermine its regulatory capacity. Senior leadership turnover and a hiring freeze have reduced review staff by roughly 15 percent, while political pressure accelerates...
Nabla: Using AI to ‘Auto-Complete’ Biologics Design
Nabla Bio, a Harvard spin‑out founded in 2020, is developing an AI‑driven platform that automatically completes biologics designs while preserving manufacturability. The technology, created in George Church’s lab, targets the persistent bottleneck of translating complex protein candidates into scalable therapeutics....
2026 Policy Outlook: Reaping What Was Sown in 2025
The 2026 policy outlook warns that the turbulence of 2025 is giving way to a deeper, more systemic shift in U.S. biomedical policy. Political and ideological forces are increasingly dictating drug‑pricing rules and regulatory decisions, eroding the traditional science‑based framework....
TAC to the Future: Where Induced Proximity Is Pointing in 2026
The targeting chimera (TAC) platform is shifting from early‑stage proof‑of‑concept to broader industry adoption as 2026 approaches. Companies are deploying next‑generation E3 ligases, cell‑surface degrader formats, and non‑proteolytic proximity mechanisms to expand target space beyond intracellular proteins. These advances promise...
JPM Lineup: New Roles Across Industry
Dozens of biotech firms and investors announced senior‑level moves ahead of the J.P. Morgan Healthcare Conference, with several companies naming new CEOs. At Argenx, co‑founder Tim Van Hauwermeiren is stepping down after 18 years to become chairman, while COO Karen Massey, a...
Nine-Digit Venture Rounds for Mirador, Kinaset
Mirador Therapeutics announced a $120 million Series B round, while KinaseT secured $95 million in a Series A financing. Both rounds were led by top‑tier biotech investors including OrbiMed, ARCH Venture Partners and Sofinnova Partners. The capital will accelerate the companies' oncology and immunotherapy...
JPM Day 1: Big Bucks for Bispecific
AbbVie announced a $5.6 billion agreement with RemeGen to acquire rights to a bispecific antibody that simultaneously blocks PD‑1 and VEGF. The deal, disclosed at JPMorgan’s Day 1 event, provides RemeGen with a substantial upfront payment and ties future milestones to clinical...
New Early Stage VC Apuri Seeks to Seed China’s Academic Discoveries
Apuri, a new Shanghai‑based early‑stage venture firm, is launching its debut fund to commercialize biotech breakthroughs emerging from China’s academic labs. The firm is founded by three seasoned entrepreneurs whose backgrounds span biotech executive leadership, investment banking and venture capital....
Haisco Steps Onto Global Stage with Blue Chip NewCo Deal
Haisco announced the creation of AirNexis, a new company focused on chronic obstructive pulmonary disease (COPD) therapeutics. The venture secured a $200 million financing round led by Frazier Capital, marking a blue‑chip endorsement. AirNexis will develop a COPD asset designed to...
Early Proof of Concept for Krystal’s Cystic Fibrosis Gene Therapy: Clinical Report
Krystal Therapeutics reported early proof‑of‑concept data from its first‑in‑human cystic fibrosis (CF) gene‑editing trial. The single‑dose, lipid‑nanoparticle delivery of a CFTR‑correcting mRNA achieved measurable gene expression in airway epithelial cells of six patients, with no serious adverse events. Pulmonary function...
The Split-Screen Story of 2026: A Letter From the Editor
The editor’s January note highlights a resurgence in biotech capital markets, with investors returning to the sector and financing activity picking up. At the same time, a “split‑screen” narrative emerges as the FDA undergoes structural changes, longstanding public‑health policies are...
Deals Not Waiting for JPM
Dealmakers kicked off 2026 with a flurry of announcements, bypassing the J.P. Morgan Healthcare Conference. Since Jan 5, three acquisitions and more than two dozen partnerships have been disclosed. The headline deal is Eli Lilly’s $1.2 billion purchase of Ventyx Biosciences. The activity...
Warm Welcome for Aktis Could Open up IPO Queue: Public Equity Report
Aktis Therapeutics closed a $350 million private‑placement at a 30 % premium, drawing strong participation from top biotech investors. The financing bolsters its gene‑editing pipeline and is viewed by Public Equity Report as a potential catalyst for a dormant IPO pipeline. Investment...
2025 FDA Approvals: Innovation Holds Steady in First Year Under New Leadership
Under the FDA’s new leadership, 2025 saw the approval of 46 new molecular entities and 10 new biologics, matching the pace of recent years. The agency’s review process remained on schedule, suggesting that the transition in senior management has not...
Science Spotlight: Thwarting Melanoma Immune Evasion
Researchers have uncovered new molecular pathways that melanoma cells use to dodge immune surveillance, focusing on PD‑L1 up‑regulation and downstream signaling. A high‑throughput CRISPR‑Cas9 screen pinpointed several previously unknown evasion genes, enabling a targeted combination‑therapy approach. Early‑phase trials combining checkpoint...
